← Leaderboards
Jian Jin
Duke University
$14,335,932
Attributed
$25,317,842
Total exposure
12
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2012–25$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,317,842 · 12
By mechanism
R01$20,535,452 · 10
U01$3,048,071 · 1
U19$1,734,319 · 1
Top collaborators
- G Greg Wang19 shared
- Ramon E Parsons8 shared
- Yong-Hui Jiang6 shared
- Marc G. Caron5 shared
- Hong Wen5 shared
- Thomas L Kash4 shared
- Bryan L Roth4 shared
- Samir Parekh1 shared
Most similar at Duke University
Same institution · by research overlap
- Marc G. Caron$32,189,154
- Robert J Lefkowitz$17,365,480
- Cathrine Hoyo$22,947,053
- Susan Kay Murphy$5,567,828
- G Greg Wang$11,565,583
Others in their field
Top investigators on “Property”
- Mitchell J Malone · Texas A&M Research Foundation$344,583,004
- Gary D Acton · University Of California-Davis$320,373,312
- Everette D Joseph · Howard University$250,079,293
- Valerie Koch · University Corporation For Atmospheric Res$247,762,266
- Antonio J Busalacchi · University Of Maryland, College Park$243,972,016
- Eric J Barron · Pennsylvania State Univ University Park$243,972,016
Research focus
PropertyDrug KineticsIn VivoIn VitroDesignCellsComplexDrug CandidateSmall MoleculePublic HealthLeadNovel Therapeutic InterventionReportingMethyltransferaseBaseTechnologyMouse ModelInnovationHistone H3BindingLysineLinkCell ModelTranslating
Grant awards (59)
Developing Lysine Methyltransferase SETD8 Selective Inhibitors for Treating Multiple Myeloma$701,330
R01 · FY2025 · CA · contact PI
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$654,354
R01 · FY2025 · CA · contact PI
Novel Inhibitors of Lysine Methyltransferases G9a and GLP for the Treatment of Alzheimer's Disease$643,355
R01 · FY2025 · AG · contact PI
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner$640,960
R01 · FY2025 · CA
Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias$514,092
R01 · FY2025 · CA · contact PI
Novel Inhibitors of Lysine Methyltransferases G9a and GLP for the Treatment of Alzheimer's Disease$661,299
R01 · FY2024 · AG · contact PI
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$621,637
R01 · FY2024 · CA · contact PI
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner$608,912
R01 · FY2024 · CA
Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias$488,387
R01 · FY2024 · CA · contact PI
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$92,168
R01 · FY2024 · CA · contact PI
Novel Inhibitors of Lysine Methyltransferases G9a and GLP for the Treatment of Alzheimer's Disease$678,549
R01 · FY2023 · AG · contact PI
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$641,266
R01 · FY2023 · CA · contact PI
Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias$503,120
R01 · FY2023 · CA · contact PI
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in cancer$479,306
R01 · FY2023 · CA
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$422,496
R01 · FY2023 · CA · contact PI
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in caner$230,678
R01 · FY2023 · CA
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$97,018
R01 · FY2023 · CA · contact PI
Discovery of First-in-class WDR5 PROTACs as a Novel Therapeutic Strategy for MLL-rearranged Leukemias$671,604
R01 · FY2022 · CA · contact PI
Dissecting and targeting canonical and non-canonical oncogenic functions of EZH2 in cancer$643,960
R01 · FY2022 · CA
Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias$503,533
R01 · FY2022 · CA · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$244,844
R01 · FY2022 · CA · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$87,357
R01 · FY2022 · CA · contact PI
Epigenetic Therapy and Prader-Willi Syndrome$555,703
R01 · FY2021 · HD
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$532,355
R01 · FY2021 · CA · contact PI
Development of Novel PROTACs Targeting the ENL YEATS Domain for Treating MLL-rearranged Leukemias$531,691
R01 · FY2021 · CA · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$249,841
R01 · FY2021 · CA · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$89,140
R01 · FY2021 · CA · contact PI
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$89,033
R01 · FY2021 · CA · contact PI
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$27,371
R01 · FY2021 · CA · contact PI
Epigenetic Therapy and Prader-Willi Syndrome$577,116
R01 · FY2020 · HD
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$532,355
R01 · FY2020 · CA · contact PI
Discovery of Selective Inhibitors for Histone Methyltransferases$330,525
R01 · FY2020 · GM · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$249,841
R01 · FY2020 · CA · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$89,140
R01 · FY2020 · CA · contact PI
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$516,385
R01 · FY2019 · CA · contact PI
Epigenetic Therapy and Prader-Willi Syndrome$395,303
R01 · FY2019 · HD
Discovery of Selective Inhibitors for Histone Methyltransferases$330,525
R01 · FY2019 · GM · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$242,348
R01 · FY2019 · CA · contact PI
Epigenetic Therapy and Prader-Willi Syndrome$165,579
R01 · FY2019 · HD
Epigenetic Therapy and Prader-Willi Syndrome$561,008
R01 · FY2018 · HD
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$532,355
R01 · FY2018 · CA · contact PI
Discovery of Selective Inhibitors for Histone Methyltransferases$330,525
R01 · FY2018 · GM · contact PI
(PQ9) Developing EZH2 Degraders for Treating Triple-Negative Breast Cancer$249,841
R01 · FY2018 · CA · contact PI
Epigenetic Therapy and Prader-Willi Syndrome$582,250
R01 · FY2017 · HD
Targeting Lysine Methyltransferases EZH2 and EZH1 for Treating MLL-rearranged Leukemias$549,730
R01 · FY2017 · CA · contact PI
Discovery of Selective Inhibitors for Histone Methyltransferases$330,525
R01 · FY2017 · GM · contact PI
DREADD2.0: AN ENHANCED CHEMOGENETIC TOOLKIT$943,003
U01 · FY2016 · MH
Chemistry Project$342,000
U19 · FY2016 · MH · contact PI
DREADD2.0: AN ENHANCED CHEMOGENETIC TOOLKIT$198,768
U01 · FY2016 · MH
DREADD2.0: AN ENHANCED CHEMOGENETIC TOOLKIT$908,902
U01 · FY2015 · MH
Creating in vivo Chemical Probes for Lysine Methyltransferases G9a and GLP$386,448
R01 · FY2015 · GM · contact PI
Chemistry Project$342,000
U19 · FY2015 · MH · contact PI
DREADD2.0: AN ENHANCED CHEMOGENETIC TOOLKIT$997,398
U01 · FY2014 · MH
Chemistry Project$342,000
U19 · FY2014 · MH · contact PI
Creating in vivo Chemical Probes for Lysine Methyltransferases G9a and GLP$316,770
R01 · FY2014 · GM · contact PI
Creating in vivo Chemical Probes for Lysine Methyltransferases G9a and GLP$34,266
R01 · FY2014 · GM · contact PI
Chemistry Project$328,319
U19 · FY2013 · MH · contact PI
Creating in vivo Chemical Probes for Lysine Methyltransferases G9a and GLP$327,258
R01 · FY2013 · GM · contact PI
Chemistry Project$380,000
U19 · FY2012 · MH · contact PI